Quantcast
Last updated on April 16, 2014 at 12:38 EDT

Latest Sufentanil Stories

2013-07-26 08:25:36

CUPERTINO, Calif., July 26, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 5, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2013-06-21 08:24:45

REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June 27, 2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21 Club, 21 West 53(rd) Street, New York, NY. Members of the AcelRx management team will present insights on...

2013-05-21 08:28:38

- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line data demonstrating that in a...

2013-05-08 16:28:10

REDWOOD CITY, Calif., May 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2013. "We continue to make progress in clinical development of our product candidates. We presented additional data at the recent American Society of Regional...

2013-05-02 16:30:00

CUPERTINO, Calif., May 2, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31, 2013. For comparison, total GAAP revenue was $41.2 million and net income was $30.8 million for the three months ended March 31, 2012. The revenue for the first quarter of 2012 included the accelerated recognition of $35.4 million in deferred...

2013-05-02 08:37:27

- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional...

2013-04-24 08:29:26

CUPERTINO, Calif., April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2013-04-24 08:29:02

- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled,...

2013-03-12 16:24:05

REDWOOD CITY, Calif., March 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2012, and provided a corporate update. (Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO) "We made important strides in the...

2013-03-04 20:22:14

- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.001) - REDWOOD CITY, Calif., March 4, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line data results demonstrating that the first of two pivotal placebo-controlled Phase 3...